Android app Apple app link

US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results

By Yahoo! Finance   |   1 month ago
US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results

Akebia Therapeutics' stock price rose 19% to US$2.26 after announcing revenues of US$160m, above expectations, but recorded a loss of US$0.33. Analysts forecast a 21% increase in revenue to US$193.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.